While the Dificid (fidaxomicin) launch has been off to a strong start in its first year with about $51.1 million in sales from July 2011 to June 2012, Optimer Pharmaceuticals Inc. is taking efforts to increase access to the drug – particularly in hospitals.
At an investor day held Oct. 8 in New York, Optimer CEO Pedro Lichtinger reviewed the steps the company has been taking to drive sales and increase use in the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?